A method for selecting cis-acting regulatory sequences that respond to small molecule effectors by Allas, Ülar & Tenson, Tanel
METHODOLOGY ARTICLE Open Access
A method for selecting cis-acting regulatory
sequences that respond to small molecule
effectors
Ülar Allas, Tanel Tenson
*
Abstract
Background: Several cis-acting regulatory sequences functioning at the level of mRNA or nascent peptide and
specifically influencing transcription or translation have been described. These regulatory elements often respond
to specific chemicals.
Results: We have developed a method that allows us to select cis-acting regulatory sequences that respond to
diverse chemicals. The method is based on the b-lactamase gene containing a random sequence inserted into the
beginning of the ORF. Several rounds of selection are used to isolate sequences that suppress b-lactamase
expression in response to the compound under study. We have isolated sequences that respond to erythromycin,
troleandomycin, chloramphenicol, meta-toluate and homoserine lactone. By introducing synonymous and non-
synonymous mutations we have shown that at least in the case of erythromycin the sequences act at the peptide
level. We have also tested the cross-activities of the constructs and found that in most cases the sequences
respond most strongly to the compound on which they were isolated.
Conclusions: Several selected peptides showed ligand-specific changes in amino acid frequencies, but no
consensus motif could be identified. This is consistent with previous observations on natural cis-acting peptides,
showing that it is often impossible to demonstrate a consensus. Applying the currently developed method on a
larger scale, by selecting and comparing an extended set of sequences, might allow the sequence rules underlying
the activity of cis-acting regulatory peptides to be identified.
Background
There are several ways in which the translation of an
mRNA can be regulated. According to the classical sce-
nario, trans factors, either protein or RNA, bind to the
mRNA and modulate the level of translation. More
recently, regulatory mechanisms not requiring trans-
acting protein or RNA molecules have been described.
First, the nascent peptide can stall the ribosome, often
in response to small molecules. This leads to the induc-
tion or repression of downstream genes [1,2]. In bac-
teria, nascent peptide:ribosome complexes respond to
macrolide group antibiotics, chloramphenicol and tryp-
tophan [3-6]. Secondly, the mRNA itself can recognize
small molecules, leading to changes in its transcription
or translation. These regulatory RNA structures are
called riboswitches [7,8].
Interestingly, the nascent peptides that regulate the
activity of the ribosome, in a similar manner in most
cases, do not share a consensus sequence [1,4]. Finding
the sequence rules is hampered by the limited number
of sequences available. Although several screens for
active peptide sequences have been published [9-12], a
general method that allows identification of regulatory
sequences responding to small molecule effectors was
lacking. Here, we describe a novel method for selecting
peptides capable of inhibiting translation in response to
different chemicals. The method allows new regulatory
elements to be constructed and might shed light on the
sequence rules underlining the activities of natural regu-
latory peptides. Although developed for identifying small
peptide sequences, the method might be applicable to
the development of synthetic riboswitches. * Correspondence: Tanel.Tenson@ut.ee
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Rationale of selection
Expression libraries for random peptides provide a use-
ful tool for isolating peptides with various properties
[11-14]. In this study, a method was developed for
selecting cis-acting sequences that sensitize the synthesis
of a specific marker protein to externally added chemi-
cals. We expected the sequences to exert activity at the
peptide level.
We built our selection scheme upon b-lactamase.
Ampicillin induces autolysis of sensitive bacteria and
b-lactamase provides resistance to it. When a random
peptide sequence added to the N-terminus of b-
lactamase (or a nucleotide sequence inserted in front of
the ORF) decreases the expression of the enzyme in
response to a specific chemical, a cell bearing this plas-
mid becomes sensitive and lyses, releasing the plasmid
into the growth medium. The sequences that specifically
respond to the compound of interest can be identified
in the plasmid DNA released under these conditions.
The set of compounds used for selection included the
antibiotics erythromycin and chloramphenicol, which
bind to the large ribosomal subunit near the peptidyl
transferase center and inhibit protein synthesis [15-18].
For both these antibiotics, cis-acting regulatory peptides
have been reported [2-4,19]. We also extended our stu-
dies to compounds that are not known to have specific
peptide response sequences. Troleandomycin is structu-
rally and functionally related to erythromycin [14], so it
is highly likely to select regulatory peptide sequences.
Homoserine lactones (HSL) are well-described bacterial
signal molecules that are produced by many different
species but not E. coli [20]. Meta-toluate, an aromatic
compound foreign to E. coli, was included to increase
the diversity of chemicals tested.
Selection of cis-acting sequences
We prepared a plasmid library in which an SD, initia-
tion codon and 21 random nucleotides were inserted in
front of the coding sequence of the b-lactamase ORF.
Transcription was controlled by the tac promoter [21].
Bacteria were transformed with the plasmid library and
the transformants were initially grown at a low concen-
tration of ampicillin. This selection step was necessary
to eliminate clones in which b-lactamase activity had
been constitutively reduced; for example, as a result of
introducing a termination codon into the random
sequence. Our initial library contained 10
6 clones, con-
taining all four nucleotides in approximately equal
amounts (21% A, 20.5% C, 25.1% G and 33.4% T). The
possible number of RNA sequences coded by a random
sequence of 21 nucleotides is over 10
12 and the number
of possible heptapeptide sequences is 1.28*10
9.
T h e r e f o r eo n l yas m a l lf r a c t i o no ft h es e q u e n c es p a c e
was sampled in our experiments. Still, we expected that
if strong sequence preference patterns are involved
these would be revealed. For example, the amino acid
preference patterns that we have observed for the
macrolide resistance peptides [11,13,14,22] would be
easily determined using the library size of the current
study.
In the next step, the cells were collected, washed to
remove ampicillin and transferred into fresh medium
containing one of the compounds used for selection.
The chemicals were used at concentrations inhibiting
t h eg r o w t hr a t eb y~ 2 0 %w i t ht h ee x c e p t i o no fH S L ,
which does not significantly inhibit cell growth. After
the cells had been grown in the presence of the chemi-
cal, ampicillin was added. If the 21-nucleotide insertion
(or the peptide encoded) inhibited b-lactamase synthesis,
the cells became sensitive to ampicillin and were lysed.
Since clones in which inhibition occurred without an
externally added chemical were removed in the first
selection step, the second step is expected to enrich for
sequences responding to the chemical. To isolate the
sequences suppressing b-lactamase production, plasmids
released from the lysed cells were isolated from the
medium and used to transform new bacteria. The selec-
tion steps described above were repeated for two more
rounds.
In the next step, we isolated individual clones and
analyzed ampicillin sensitivity in the absence and pre-
sence of the compound under study; 4-7% of the clones
were more sensitive to ampicillin than the control con-
struct in the presence of the test compound. The plas-
mids were isolated from these cells and the region
randomized in the original library was sequenced. For
every test compound, at least 10 clones were chosen for
further analysis.
Selected sequences
All the compounds used selected for sequences that
sensitized the bacteria to ampicillin (Table 1, Additional
file 1). The activities are reported as ratios of optical
densities measured in the absence and presence of the
corresponding compound. We confirmed that the
sequence variations concern only the randomized
region, with no PCR generated mutations in the other
parts of the b-lactamase coding ORF by sequencing the
plasmid from clones giving the strongest response (from
six strongest clones per selection). We recognized no
common RNA sequence consensus among the clones
selected on any of the compounds. Similarly, no com-
mon sequence motifs were found at the peptide level.
Nevertheless, the amino acid compositions of peptides
selected on different compounds revealed some trends.
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Page 2 of 13Table 1 The activities of the constructs isolated as measured in three reporter systems
Erythromycin activity in reporter system
name amino acid sequence lactamase galactosidase GFP
E1 Asp His Tyr Ser Arg Ile Val 2.02 (±0.11) 1.46 (±0.10) ND
E2 Val Ile Gly Arg Asn Ser Phe 1.70 (±0.09) 1.85 (±0.04) ND
E3 Gly Thr Ser Leu Gly Arg Gly 1.66 (±0.09) 1.61 (±0.08) ND
E4 Leu Gly Ile Arg Ser Gly Tyr 1.63 (±0.11) 2.04 (±0.03) 1.62 (±0.12)
E5 Ile Ser Val Trp Leu Val Ala 1.58 (±0.16) 1.95 (±0.05) 1.55 (±0.01)
E6 Gly Trp His Leu Arg Leu Val 1.56 (±0.14) 1.95 (±0.06) 1.33 (±0.05)
E7 Val Gly Leu Phe Ala Asn Gly 1.54 (±0.12) 1.53 (±0.08) ND
E8 Ala Ser Ser Val Ser His Leu 1.53 (±0.21) 1.73 (±0.12) ND
E9 Phe Ile Leu Ser Ile Ser Leu 1.48 (±0.17) 1.63 (±0.06) ND
E10 Leu Val Leu Cys Asn Leu Leu 1.46 (±0.07) 1.41 (±0.04) ND
control - 1.06 (±0.13) 1.26 (±0.06) 1.15 (±0.04)
Chloramphenicol activity in reporter system
name amino acid sequence lactamase galactosidase GFP
C1 Gln Glu Arg Ala Thr Gly Val 3.06 (±0.18) 2.46 (±0.06) 1.95 (±0.02)
C2 Arg Gly Gly Phe Ser Asn Glu 2.89 (±0.06) 1.73 (±0.08) ND
C3 Glu Asn Ala Pro Ser Tyr Asp 2.62 (±0.10) 2.00 (±0.14) ND
C4 Ser Ser Gly Ala Phe Gly Thr 2.49 (±0.04) 1.74 (±0.12) ND
C5 Arg Val Pro Pro Arg Arg Cys 2.35 (±0.14) 2.08 (±0.09) ND
C6 Phe Leu Glu Val Gly Cys Ser 2.32 (±0.11) 2.40 (±0.03) 3.11 (±0.02)
C7 Gly Arg Gln Val Gly Arg Val 2.14 (±0.10) 1.72 (±0.11) ND
C8 Ser Val Cys Cys Phe Val Phe 2.01 (±0.08) 2.05 (±0.13) ND
C9 Cys Trp Gly Ile Asp Met Ala 2.00 (±0.15) 2.17 (±0.04) 1.91 (±0.05)
C10 Lys Thr Tyr Val Gly Lys Ile 1.93 (±0.12) 1.95 (±0.07) ND
control - 1.41 (±0.06) 1.43 (±0.12) 1.43 (±0.08)
Troleandomycin activity in reporter system
name amino acid sequence lactamase galactosidase GFP
T1 Asn Leu Glu Ser Val Leu Ser 2.03 (±0.14) 2.36 (±0.11) 0.46 (±0.02)
T2 Arg Val Arg Asp Val Phe Tyr 1.78 (±0.05) 1.53 (±0.10) ND
T3 Arg Gly Glu Gly Trp Gly Leu 1.67 (±0.15) 1.63 (±0.14) ND
T4 Gly Arg Gly Arg Cys Val Ser 1.65 (±0.06) 2.14 (±0.10) 0.70 (±0.21)
T5 Ser Ala Glu Ala Phe Arg Ala 1.58 (±0.08) 1.51 (±0.07) ND
T6 Ile Leu Met Leu Arg Arg Ser 1.56 (±0.13) 1.62 (±0.11) ND
T7 Gly Gly Ser Ala Phe Ile Glu 1.45 (±0.13) 1.53 (±0.04) ND
T8 Glu Cys Gln Ser Arg His Met 1.37 (±0.10) 1.67 (±0.08) ND
T9 Ile Ser Ile Met Arg Arg Cys 1.21 (±0.08) 1.85 (±0.06) 0.81 (±0.10)
T10 Pro Ser Ala Arg Ile His Arg 1.20 (±0.11) 1.38 (±0.13) ND
control - 1.11 (±0.13) 1.54 (±0.03) 0.91 (±0.05)
Meta-toluate activity in reporter system
name amino acid sequence lactamase galactosidase GFP
M1 Glu Arg Thr Tyr Ile Met Tyr 2.35 (±0.13) 0.99 (±0.08) 1.34 (±0.07)
M2 Ser Trp Gly Leu Ala Ala Lys 2.24 (±0.08) 0.73 (±0.09) 1.39 (±0.06)
M3 Arg Ala Asp Arg Phe Lys Phe 2.14 (±0.04) 1.10 (±0.01) 1.86 (±0.15)
M4 Lys Tyr Gln Leu Leu Ile Cys 1.90 (±0.12) 1.21 (±0.06) 1.24 (±0.05)
M5 Gly Trp His Arg Trp Trp Tyr 1.84 (±0.06) 0.97 (±0.06) 1.26 (±0.04)
M6 Gly Lys Phe Gly Ser Ala Ser 1.81 (±0.11) 1.04 (±0.05) 1.38 (±0.12)
M7 Leu Val Val Thr Thr Leu Ile 1.80 (±0.08) 0.89 (±0.04) 1.69 (±0.15)
M8 Gly Lys Leu Tyr Arg Tyr Asp 1.75 (±0.05) 0.98 (±0.03) 1.65 (±0.13)
M9 Ile Ser Val Trp Leu Val Ala 1.67 (±0.05) 0.94 (±0.09) 0.97 (±0.05)
M10 Ser Arg Val Leu Val Ser Cys 1.64 (±0.06) 1.06 (±0.02) 2.23 (±0.22)
control - 1.34 (±0.04) 0.89 (±0.11) 1.63 (±0.05)
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Page 3 of 13Peptides selected on erythromycin were enriched in leu-
cine and serine; sequences selected on chloramphenicol
were enriched in glycine; troleandomycin selected for
enrichment in arginine; and sequences selected on HSL
were enriched in valine (Table 2).
Activity of the selected sequences tested with alternative
reporter systems
The sequences isolated might respond to specific chemi-
cals only in the presence of ampicillin or might work only
if inserted in front of b-lactamase. To test for such possi-
ble context effects we fused the selected sequences to the
ORFs encoding b-galactosidase and GFP. b-galactosidase
expression was measured in Miller units and GFP expres-
sion was determined by flow cytometry, measuring the
green fluorescence of the cells. The activities of the
selected sequences are reported as ratios of reporter gene
activity measured in the absence and presence of the cor-
responding chemical (Table 1).
Sequences selected on erythromycin or chlorampheni-
col responded to the corresponding compound in the
context of both additional reporter genes. However, only
some of the sequences selected on troleandomycin were
active in the context of b-galactosidase and none worked
with the GFP reporter. Only a few of the meta-toluate-
responsive sequences showed weak activity with reporter
systems other than the original b-lactamase. The HSL
sequences were tested only in front of the GFP reporter.
The activities were very weak, if significant at all.
The sequences selected with erythromycin are active
as peptides
There are two possible ways in which the selected
sequences might affect protein synthesis. First, the
sequences could affect gene expression by forming
riboswitch mRNA structures, able to bind chemicals
directly and regulate gene expression. Alternatively, they
may be functional at the peptide level via specific inter-
actions between the chemicals, peptides and the ribo-
some. To discriminate between these possibilities, we
introduced synonymous mutations into one chloram-
phenicol and two erythromycin responsive sequences
fused to b-galactosidase, changing the mRNA sequence
but preserving the peptide sequence (Figure 1). When
possible, the codons were substituted with synonymous
ones that possess the most similar frequency of usage
[23]. A b-galactosidase assay was used to compare the
substituted variants with the original sequence. As
s h o w ni nF i g u r e1 ,w ef o u n dn osignificant differences
between the expression levels of the initial constructs
and synonymous codon-substituted variants.
To test whether a selected sequence is active at the
level of the translated peptide, several non-synonymous
mutations changing the amino acid sequence were
introduced into the erythromycin responsive element
that was most active in the context of b-galactosidase.
As shown in Figure 2, the single amino acid substitu-
tions influenced the activity of the peptide. The activity
was greater when the peptide was made more hydro-
phobic (M8). In contrast, introducing negatively charged
aspartic acid residues decreased the activity (constructs
M6, M9, M11, M13). It has to be noted that we do not
have a negative control, a sequence that does not
respond to erythromycin at all. Estimating the back-
ground from the cross-activity tests (Figure 3, described
below) we conclude that erythromycin has unspecific
effect in the b-galactosidase test system and the back-
ground is above one. Therefore the effect of mutations
Table 1 The activities of the constructs isolated as measured in three reporter systems (Continued)
HSL activity in reporter system
name amino acid sequence lactamase galactosidase GFP
H1 Thr Lys Leu Ser Pro Leu Ile 1.44 (±0.11) ND 1.23 (±0.06)
H2 Ala Leu Pro Val Val Val Ile 1.39 (±0.05) ND 1.49 (±0.06)
H3 Gly Ala Val Asp Val Leu Val 1.37 (±0.13) ND 1.24 (±0.12)
H4 Asp Tyr Val Asp Cys Pro Arg 1.35 (±0.06) ND 1.44 (±0.04)
H5 Phe Leu Cys Pro His Asp Ser 1.33 (±0.08) ND 1.18 (±0.02)
H6 Glu Leu Phe Val Pro Tyr Cys 1.23 (±0.07) ND ND
H7 Lys Ala Ser Leu Asp Pro Leu 1.21 (±0.09) ND ND
H8 Gly Ala Phe Met Val Asp Ser 1.13 (±0.07) ND ND
H9 Asn Ala Ile Ala Ile Arg Arg 1.12 (±0.15) ND 1.56 (±0.11)
H10 Asn Val Leu Ala Phe Lys Gly 1.11 (±0.10) ND 1.26 (±0.04)
control - 0.96 (±0.11) ND 1.32 (±0.05)
The activity is shown as a ratio of marker gene expression measured in the absence and presence of the corresponding compound. The plasmids without 5’
extensions in the marker gene coding ORFs, p177-NotI, pPOTZ-HindIII and pETGFP, were used as controls for b-lactamase, b-galactosidase and GFP activity
respectively. Amino acid sequences of the peptides encoded by the randomized part of the plasmid are shown. Standard errors are indicated. ND - not
determined.
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Page 4 of 13present in construct M9 could be considered being close
to inactivation. The effects of mutations leading to
amino acid changes were greater than those that pre-
served the peptide sequence (described above). We
therefore conclude that the erythromycin responsive
sequences act as peptides.
The ligand specificity of the selected sequences
The specificity of the isolated peptides for the compounds
used in selection was estimated in cross-inhibition experi-
ments using the b-galactosidase and GFP reporter systems.
For experiments with the b-galactosidase reporter system,
we chose three peptides from each group (excluding the
Table 2 Number of amino acids in the randomized part of the sequences (Table 1), analyzed according to the
chemical used in selection
erythromycin chloramphenicol troleandomycin meta-toluate HSL
Amino
acid
Total
number
Sequences Total
number
Sequences Total
number
Sequences Total
number
Sequences Total
number
Sequences
A 3344535476
C 1154332233
D 1122112265
E --44551111
F 3354333243
G 95 1 0 7735433
H 33--221111
I 6522544443
K --21--5532
L 1 3 811538697
M --11331111
N 332211--22
P --3211--66
Q --221111--
R 5574 1 3 86532
S 1 0 765996444
T1 1 3 3 - - 3 2 1 1
V 87864363 1 0 6
W 22111153--
Y 2222116422
“Total number” indicates the total number of amino acids in the sequence group; “Sequences” indicates the number of sequences containing the particular
amino acid.
Figure 1 The effects of mRNA structure on the activities of the constructs. The activity of b-galactosidase fused with original sequences E1,
E5 and C7 was compared to the activities of variants containing synonymous substitutions (marked with asterisks). The nucleotide sequences of
the constructs are shown. The expression of b-galactosidase marker protein was measured 3 h after induction with IPTG in the absence and
presence of the corresponding antibiotic. The activity of each construct is shown as a ratio of Miller units measured in the absence and
presence of antibiotic.
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Page 5 of 13sequences selected with HSL) that showed the strongest
inhibition in response to their compound of selection. We
also tested the ErmC regulatory peptide, known from the
literature to respond to erythromycin, and a mutant var-
iant of one of the selected peptides with increased activity.
For the GFP reporter, three sequences of each class were
tested, including those selected with HSL.
As expected, the ErmC control sequence responded to
erythromycin. The effect was in the same order of mag-
nitude as the activities of the sequences selected in the
current study. In the b-galactosidase context, all three
sequences of the erythromycin group responded to both
erythromycin and chloramphenicol (Figure 3, panel A).
In the GFP test system, there was a specific response
only to erythromycin (Figure 4, panel A). This observa-
tion shows that the reporter context influences both the
magnitude and specificity of the response.
The chloramphenicol sequences responded most
strongly to chloramphenicol in both reporter systems
(Figure 3, panel B and Figure 4, panel B). Two of the
troleandomycin sequences with the strongest effects on
b-lactamase expression responded to the compound
when tested with the b-galactosidase system (Figure 3,
panel C). Surprisingly, these sequences did not inhibit
Figure 2 The effects of amino acid substitutions in the E4 sequence. Amino acid substitutions in mutants are marked in capital letters. All
sequence variants were tested as b-galactosidase fusions. The expression of b-galactosidase marker protein was measured 3 h after induction
with IPTG in the absence and presence of the corresponding antibiotic. The activity of each construct is shown as a ratio of Miller units
measured in the absence and presence of antibiotic.
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Page 6 of 13Figure 3 Cross-responses of the sequences to different compounds as measured in the b-galactosidase reporter system. The sequences
originally selected on erythromycin (A), chloramphenicol (B), troleandomycin (C) and meta-toluate (D) were tested. Constructs containing ErmC
leader peptide and a mutant of E4 peptide (Mut8, Figure 2) were included. The expression of b-galactosidase marker protein was measured 3 h
after induction with IPTG in the absence and presence of compound (E-erythromycin, C-chloramphenicol, T-troleandomycin, M-meta-toluate).
The activity of each construct is shown as a ratio of Miller units measured in the absence and presence of the compound. Gray bars indicate the
activity in the presence of the compound which was used for selecting the sequence.
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Page 7 of 13Figure 4 Cross-responses of the sequences to different compounds as measured using the GFP reporter system.T h es e q u e n c e s
originally selected on erythromycin (A), chloramphenicol (B), troleandomycin (C), meta-toluate (D) and homoserine lactone (E) were tested. The
expression of GFP marker protein was measured 3 h after induction with IPTG in the absence and presence of the compound (E-erythromycin,
C-chloramphenicol, T-troleandomycin, M-meta-toluate, H-homoserine lactone). The activity of each construct is shown as a ratio of GFP
fluorescence measured in the absence and presence of the compound. Gray bars indicate the activity in the presence of the compound which
was used for selecting the sequence.
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Page 8 of 13GFP synthesis in a troleandomycin-dependent manner.
In fact, addition of troleandomycin led to increased GFP
synthesis (Figure 4, panel C). This shows again that the
activity of a selected sequence is strongly influenced by
the reporter. Moreover, some of the meta-toluate
sequences seemed to have a specific effect when tested
with GFP but not with b-galactosidase (Figure 3, panel
D and Figure 4, panel D). One of the three HSL
sequences seemed to have specific activity when tested
in front of GFP. In conclusion, most of the selected pep-
tides are specific for the compound that was used in the
selection, although the effect depends strongly on the
reporter system.
Discussion
Cis-acting small peptides causing ribosome stalling in
response to specific small molecules - erythromycin,
chloramphenicol, tryptophan, arginine and polyamines -
have been described previously [2-6,24-26]. In all these
systems the ribosome is stalled on the mRNA in a man-
ner depending on the peptide and the inducing chemi-
cal. It has been suggested that the stalling is initiated by
a specific interaction between the chemical and the nas-
cent peptide in the ribosome exit tunnel [1,19]. In sev-
eral cases it has been shown that stalling occurs before
complete translation of the ORF, indicating that it does
not require the termination codon. Moreover, an argi-
nine response peptide works as the N-terminal fusion of
a reporter protein [27]. This encouraged us in designing
our library to express proteins with random N-terminal
sequences that could potentially regulate translation.
We have developed a method that allows us to screen
for synthetic regulatory sequences responding to chemi-
cal compounds. A method of this kind should include
positive selection for clones responding to the chemical
and negative selection for removing clones with consti-
tutive responses. This was achieved by using a plasmid
with b-lactamase that causes ampicillin resistance. A
random sequence was inserted into the beginning of the
ORF and selection was carried out using three antibio-
tics that target the ribosome (erythromycin, troleando-
mycin and chloramphenicol [15-18]), one bacterial
signal molecule (HSL [20]), and a non-biological aro-
matic compound (meta-toluate). It has to be noted that
to exert its activity, b-lactamase has to be exported into
the periplasm. The export signal is in the N-terminus of
the protein [28,29]. In all our constructs the natural
export sequence follows the randomized part. It has
been shown that the export sequence can withstand
many mutations without complete loss of b-lactamase
activity [30]. We expect that fast majority of the library
constructs can support b-lactamase export as the fre-
quency of constructs not able to grow in the presence
of ampicillin (around 30%) corresponds to the expected
frequency of termination codons in the randomized part
of the sequence. Still, the possibility remains that con-
structs are selected were the small chemicals under
study suppress b-lactamase export in the peptide
sequence dependent manner. These effects should not
be present when tested in the context of the alternative
reporter proteins. To study this possibility, the selected
sequences were tested with two additional reporters,
b-galactosidase and GFP. The erythromycin and chlor-
amphenicol sequences retained activity in both
these reporter systems. Surprisingly, only few of the
troleandomycin sequences retained activity in the b-
galactosidase system and all the sequences tested with
GFP were inactive. This shows that the reporter context
modulates the effect of the regulatory sequence to a
large extent. The context effect points to the inherent
limitation of the selection system described here and
other similar systems that might be constructed; it is
highly probable that some active sequences will be
missed because they do not work in the context of the
reporter chosen.
Our library design created a randomized part of the
mRNA, leading to the production of a peptide library.
The selected sequences may therefore act at the level of
mRNA or peptide. To discriminate between these possi-
bilities, one chloramphenicol and two erythromycin
responsive sequences were subjected to mutational ana-
lysis. Changing the mRNA structure by introducing
synonymous mutations did not change the activities of
the sequences; in contrast, several mutations led to
amino acid substitutions that changed the activities of
the erythromycin sequences. This indicates that the
activity is mediated by the protein sequence. Although
we have not performed similar experiments on the
other sequence classes selected, we consider it probable
that these sequences also act at the peptide level. It is
also possible that the N-terminal sequences do not
influence the synthesis of the reporter protein but regu-
late the stability or activity of the reporter. To test this
possibility, the erythromycin responsive sequences E4,
E5 and the chloramphenicol responsive sequence C6
were studied with the GFP reporter. Transcription was
induced with IPTG, followed by removal of the inducer
by changing the growth medium. All cultures were
divided into three aliquots. Erythromycin was added to
the first aliquot, chloramphenicol to the second aliquot
and the third aliquot was serving as a control. As the
inducer was removed, the total fluorescence of the con-
trol culture remained constant. Addition of either anti-
biotic did not cause reduction of the total GFP
fluorescence of the culture (data not shown) leading to
the conclusion that the compounds do not influence the
activity or stability of the mature reporter protein.
This indicates that the sequences act during synthesis of
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Page 9 of 13the reporter protein suggsting a regulatory interaction in
the ribosome.
In the current work we present the data as ratios of
reporter gene activities measured in the absence and
presence of the effector chemical. In the absence of
effect, this ratio is expected to be one. The largest
induction levels we found were around 2.5 fold. This is
small in comparison to the reported effects of regulatory
nascent peptides [26,31]. In our system, the previously
described ErmC leader peptide sequence responding to
erythromycin causes an effect similar in magnitude to
the sequences we selected from the random library. The
difference between the ErmC activity in its natural con-
t e x ta n de x p r e s s e df r o mo u rs e l e c t i o nc o n s t r u c tm i g h t
be attributed to the special arrangements of ORFs cod-
ing for natural regulatory cis-acting peptides. The nat-
ural bacterial regulatory ORFs are upstream of the main
ORFs, the translation initiation site of the main ORF
being trapped within a strong mRNA secondary struc-
ture. In response to a small chemical, erythromycin in
the case of ErmC, the ribosome is stalled on the
upstream ORF causing melting of the RNA secondary
structure and opening of the translation initiation region
of the main ORF, leading to synthesis of the enzyme
responsible for erythromycin resistance [3,32]. This
switching of mRNA structure might amplify the effect
of ribosome stalling. The similarity in magnitude of the
effects caused by the ErmC and sequences selected from
the library suggests that although the observed effects
are relatively small, the system might be useful for eluci-
dating the sequence rules responsible for the functional
interactions between nascent peptide chains, ribosomes
and the inducing chemicals that operate in natural
systems.
We have observed previously that the expression of
specific small peptides can cause resistance against
macrolide antibiotics, including erythromycin
[11,13,14,22,33]. Macrolide antibiotics bind to the nas-
cent peptide exit tunnel, stop growth of the polypep-
tide chain and cause dissociation of peptidyl-tRNA
from the ribosome [15,17,34]. The resistance peptides
act as a “bottle brush” causing release of the drugs
from the ribosome [35]. The erythromycin resistance
peptides have to be between four and six amino acids
long [11], the drug being ejected during the termina-
tion event [35]. If the termination codon is replaced by
as e n s ec o d o n ,t h er i b o s o m ei ss t a l l e do nt h em R N A .
We have speculated previously that the erythromycin
resistance peptides are mechanistically related to the
Erm leader peptides, the difference between possible
outcomes (either drug ejection or ribosome stalling)
being determined by the location of the termination
codon [35]. We have used a library expressing random
pentapeptides to select for sequences conferring resis-
tance to different macrolides [11,13,14]. Interestingly,
leucine is common in erythromycin resistance pep-
tides, in line with our finding that leucine-rich
sequences are selected when erythromycin is used as
effector compound. Similarly, peptides conferring resis-
tance to oleandomycin, a macrolide very similar to tro-
leandomycin, are positively charged, in line with the
enrichment with arginine observed in the current
study. These observations again suggest that the
mechanisms of peptide-mediated macrolide resistance
and nascent peptide-mediated regulation of gene
expression are similar.
Comparing the sequences selected with one chemical,
we can see enrichment with certain amino acids but
cannot define a consensus sequence. This is in line
with the sequence conservation of natural cis-acting
regulatory peptides, in whichac o n s e n s u ss e q u e n c ei s
often hard to define. Therefore, it is currently very
hard or impossible to find the ORFs encoding cis-act-
ing regulatory peptides by comparing genomic
sequences. Our currently developed method might be
employed to investigate these issues by screening a
large number of sequences, which would allow more
complex sequence features than a simple consensus to
be defined. The recent observation that small ORFs,
widespread in all genomes, are translated more fre-
quently than previously expected underlines the impor-
tance of these studies [36].
Conclusion
A method for selecting cis-acting regulatory sequences
has been developed. Although the magnitude of the
effects is smaller than in the natural context, the system
could be used for elucidating the sequence rules under-
lying natural regulatory systems.
Methods
Antibiotics, chemicals and bacterial strains
Erythromycin and chloramphenicol were from Amresco
and Applichem respectively. Troleandomycin, meta-tolu-
ate and ONPG (ortho-nitrophenyl-b-galactoside) were
from Sigma-Aldrich. HSL (N-(3-oxohexanoyl)-L-homo-
serine lactone) was prepared as described in [37]. E. coli
NovaXG Zappers™ (Novagen) [mcrA Δ(mcrC-mrr)
endA1 recA1 80dlacZΔM15 ΔlacX74 araD139 Δ(ara-
leu)7697galU galK rpsL nupG l-tonA F’[lacIq Tn10]
(TetR)] electrocompetent cells were used for electro-
poration of the library plasmids. In all other experi-
ments, DH5a [fhuA2 Δ(argF-b-galactosidase)U169 phoA
glnV44 F80 Δ(b-galactosidase)M15 gyrA96 recA1 relA1
endA1 thi-1 hsdR17] strain was used.
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The plasmid library containing seven random codons in
front of the b-lactamase ORF was prepared following a
two-step procedure:
(1) The vector pACYC177 (Fermentas) was amplified
using the oligonucleotides pACYC177-1 (bearing a
Shine-Dalgarno sequence) and pACYC177-2 (containing
mutated tac promoter) (Additional file 2). In the same
PCR reaction, NotI restriction sites were introduced at
both ends of the PCR fragment. After restriction with
NotI, complementary cohesive ends of the PCR frag-
ment were ligated to form a circular DNA molecule.
The plasmid obtained, p177-NotI, contains a NotI site
between the lac operator sequence and the initiator
codon of the b-lactamase ORF.
(2) To prepare a plasmid expression library, p177-NotI
was amplified using oligonucleotides p177-BamHI and
p177-BamHI2 (Additional file 2), each containing a
BamHI site at the 5’ end. p177-BamHI2 contained a
DNA segment corresponding to the initiator codon AUG
and 21 random nucleotides in front of a region comple-
mentary to the 5’ end of the b-lactamase-encoding ORF.
The PCR fragment was restricted with BamHI and its
ends were ligated together, thus creating a plasmid library
pAC-Lib. Since pAC-Lib does not contain the NotI site,
the ligation mixture was incubated with NotI after inacti-
vation of T4 DNA ligase to ensure that the library con-
tained no traces of p177-NotI.
Selection of active sequences
NovaXG Zappers electrocompetent cells were electropo-
rated with the plasmid library. A 200 μl aliquot of cells
was plated on a solid medium containing 25 μl/ml kana-
mycin to determine the efficiency of transformation.
Electroporated cells were grown at 37°C in 50 ml LB
medium containing 50 μl/ml ampicillin and 25 μl/ml
kanamycin with shaking until the OD600 reached 1. The
culture was then diluted to OD600 0.3 and grown to
OD 1 in the presence of the same antibiotics. Cells were
collected by centrifugation and washed with LB medium
to remove the traces of ampicillin. The washed cells
were used to prepare a new dilution (OD 0.3) in 50 ml
LB containing kanamycin (25 μl/ml). At this point, the
selecting substance was added at a concentration known
to inhibit cell growth by ~20%, with the exception of
homoserine lactone that does not inhibit cell growth (30
μg/ml erythromycin, 1 μg/ml chloramphenicol, 300 μg/
ml trolenadomycin, 15 mM meta-toluate or 1 mM
homoserine lactone). The inhibitory concentrations were
determined as described in [38]. After growing the cells
for 3 h, the culture was diluted to OD600 0.1 and grown
under the same conditions as before, using the same
selecting substance. When the OD600 reached 0.6, ampi-
cillin was added to a final concentration of 400 μl/ml.
After the cells had been grown for another hour, the
plasmid was isolated from the medium: the cells were
removed by centrifugation and DNA was precipitated by
adding NaCl to a final concentration of 200 mM fol-
lowed by 0.7 volumes of isopropanol. After centrifuga-
tion at 10,000 × g for 15 min, the DNA was dissolved in
water. The isolated plasmids were used in further trans-
formations. The selection procedure was repeated three
times.
In the next phase of selection, the plasmids isolated
from the liquid media were used to transform DH5a
competent cells. The colonies obtained were tested for
sensitivity to the selecting substance of interest in the
presence of ampicillin. Cells were grown in 2 ml LB
medium overnight, then the culture was diluted to OD
0.1 and transferred to a 96-well microtiter plate in
duplicate. Ampicillin was added to a final concentration
of 100 μl/ml to both samples; the selecting substance
was added, at the concentration that inhibited cell
growth by ~20%, to the test sample only. A culture car-
rying p177-NotI plasmid was used as reference. Samples
were grown at 37°C with shaking. The OD of the cul-
tures was recorded after 5 h. In every pair of wells, the
OD600 determined in the absence of the selecting com-
p o u n dw a sd i v i d e di n t ot h a tm e a s u r e di nt h ep r e s e n c e
of the compound. Clones that were more sensitive than
the control plasmid to the test compound were sub-
jected to the next round of testing. Overnight cultures
were used to prepare a series of samples, each contain-
ing 100 μl/ml ampicillin and a defined concentration of
test compound. The concentrations of test compounds
were selected to cover a range from zero inhibition to
twice the concentration used in the first phase of selec-
tion. The samples, diluted to OD600 0.1, were trans-
ferred to 96-well microtiter plates. After 5 h growth, the
OD600 was measured and inhibition curves were
calculated.
Cloning and mutagenesis
Sequences corresponding to the selected peptides were
fused to both b-galactosidase and GFP ORFs. In the first
case, a HindIII linker was inserted into the BamHI site of
plasmid pPOTZ, which carries a gene for b-galactosidase
and confers resistance to ampicillin (the plasmid is a deri-
vative of pPOT1 [33]; sequence provided as Additional
file 3). The plasmid obtained, pPOTZ-HindIII, was par-
tially cut with KpnI. A 7080 bp DNA fragment purified
from an agarose gel was subsequently cut with HindIII,
followed by purification of a 7006 bp fragment. This frag-
ment was ligated to a HindIII/KpnI-digested PCR pro-
duct that had been amplified from the library plasmid
using primers b-galactosidase-KpnI and b-galactosidase-
HindIII (Additional file 2) and contained sequences for
the lac operator, tac promoter and the peptide tested. To
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cleotides GFP Nhe linker 1 and GFP Nhe linker 2 (Addi-
tional file 2) were annealed, thus forming a linker, which
was inserted at the BamHI site of plasmid pETGFP [39].
A 55 bp fragment containing SD and the sequence cod-
ing for the selected peptide was amplified by PCR from
pPOTZ-based constructs using the primers GFP cloning
1 and GFP cloning 2 (Additional file 2). The amplified
fragments were ligated between the NheI and BamHI
sites of the modified pETGFP.
In some experiments, the selected peptide sequences
fused to b-galactosidase in pPOTZ were mutated. This
was achieved by PCR, using a long oligonucleotide con-
taining sequences complementary to regions located
upstream and downstream of the mutated sequence
(Mut 1 to Mut10, Orf 2903-24, Orf 1804-16 and Orf
2501-02 in Additional file 2). The reverse oligonucleo-
tide primer Orf-ClaI containing the ClaI site was com-
plementary to the region inside b-galactosidase.T h e
amplified fragment was restricted with BamHI/ClaI and
inserted into the pPOTZ-Lib vector, from which the
BamHI/ClaI fragment had been previously detached.
b-galactosidase assay
b-galactosidase was assayed by a modification of Miller’s
method [40]. Cells transformed with a plasmid expres-
sing the protein of interest were grown overnight at 37°
C in LB medium containing 100 μg/ml ampicillin. The
cultures were diluted with fresh medium to OD600 0.05
in duplicate. IPTG (final concentration 1 mM) and
ampicillin (100 μg / m l )w e r ea d d e dt ob o t hr e p l i c a t e
samples. Erythromycin, chloramphenicol, troleandomy-
cin or meta-toluate was added to the first at a concen-
tration that inhibited cell growth by ~20%; there were
no additions to the second. Samples for the assay were
collected 3 h after induction of b-galactosidase expres-
sion. The OD600 of the cultures was recorded. Aliquots
(50 μl) were removed from the samples and added to a
mixture containing 350 μl Z-buffer [40], 5 μl chloroform
and 10 μl 0.1% SDS. After vortexing, the reaction tubes
were incubated for 5 min at 30°C, then 80 μl4m g / m l
ONPG was added and the reaction mixture was incu-
bated for 20 min at room temperature. The reaction
was stopped by adding 200 μl1 MN a 2CO3 and the
tubes were centrifuged at 13,000 rpm for 2 min. The
OD of the supernatant was measured at 420 nm and
550 nm. Miller units were calculated using the following
formula:
The ability of the selected sequences to inhibit transla-
tion in the presence of the given compound was esti-
mated as a ratio of Miller units calculated in the
absence and presence of the compound.
Flow cytometry
For flow cytometry, the cells were grown as for the
b-galactosidase assay, in a medium containing kanamy-
cin (25 μg/ml) instead of ampicillin. Samples from grow-
ing cultures collected 3 h after the induction of GFP
expression were diluted with PBS and transferred to 96-
well microtiter plates. To measure GFP expression
levels, a flow cytometer LSR II and High Throughput
Sampler (Becton-Dickinson Bioscience) were used with
a laser beam maximum at 488 nm. At least 50,000
counts were acquired for each sample.
Additional material
Additional file 1: Sequences of the RNAs coded by the randomized
regions of the plasmids isolated in the selection.
Additional file 2: Oligonucleotides used in the study.
Additional file 3: Sequence of the plasmid pPOTZ.
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